FDA Accepts Amgen's New Drug Application For Novel Intravenous Calcimimetic Etelcalcetide
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq futures surge 2% as chip outlook calms AI jitters; inflation data awaited
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Cytokinetics (CYTK) and Amgen Inc. (AMGN) Announce COSMIC-HF Data; Roth Capital Raises Price Target to $22
November 9, 2015 7:32 AM ESTRoth Capital maintained a Buy rating on Cytokinetics (NASDAQ: CYTK), and raised the price target to $22.00 (from $18.00), following announced full data from COSMIC-HF at AHA. The large data set was announced jointly by Cytokinetics and global partner Amgen (NASDAQ:... More
Amgen's (AMGN) NDA for Etelcalcetide Accepted by FDA
November 6, 2015 4:02 PM ESTAmgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Amgen's New Drug Application (NDA) for etelcalcetide (formerly AMG 416) for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) on hemodialysis. If approved, etelcalcetide will be the first calcimimetic agent that can be administered... More
